title: Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy.
abstract: We evaluated the safety and efficacy of a twice daily regimen containing 400 mg of indinavir and 100 mg of ritonavir in 32 human immunodeficiency virus (HIV)-infected women during pregnancy. The median indinavir trough concentration was 208 ng/ml during the third trimester. At delivery, 26 of 28 women on indinavir-ritonavir had HIV RNA levels of <200 copies/ml. No infant was HIV infected. These data are encouraging for the use of this combination for prevention of mother-to-child transmission of HIV.
authors.affiliation: AP-HP, Department of Infectious Diseases, Pitie-Salpetriere Hospital, 47 Boulevard de l'Hôpital, 75013 Paris, France. jade.ghosn@bct.aphp.fr
authors.forename: Jade
authors.initials: J
authors.lastname: Ghosn
authors.forename: Ines
authors.initials: I
authors.lastname: De Montgolfier
authors.forename: Chantal
authors.initials: C
authors.lastname: Cornélie
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Dominguez
authors.forename: Claire
authors.initials: C
authors.lastname: Pérot
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Anne-Geneviève
authors.initials: AG
authors.lastname: Marcelin
authors.forename: Michèle
authors.initials: M
authors.lastname: Pauchard
authors.forename: Zineb
authors.initials: Z
authors.lastname: Ouagari
authors.forename: Manuela
authors.initials: M
authors.lastname: Bonmarchand
authors.forename: Rachid
authors.initials: R
authors.lastname: Agher
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.forename: François
authors.initials: F
authors.lastname: Bricaire
authors.forename: Marc
authors.initials: M
authors.lastname: Dommergues
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Roland
authors.initials: R
authors.lastname: Tubiana
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000627:therapeutic use*; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D011256:Pregnancy Outcome; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019469:Indinavir; D019438:Ritonavir